Kolexia
Abdeddaim Cyril Oncologie médicale
Abdeddaim Cyril
Oncologie médicale
Centre Oscar-Lambret
Lille, France
84 Activités
265 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Carcinomes Tumeurs de l'endomètre Récidive tumorale locale Carcinome épidermoïde Carcinome épithélial de l'ovaire Instabilité des microsatellites Carcinome pulmonaire à petites cellules Tumeurs du poumon

Collaborateurs

Voir plus
Berton Dominique
Berton Dominique
Institut de cancérologie de l'Ouest, Saint-Herblain, France
Floquet Anne
Floquet Anne
Institut Bergonié, Bordeaux, France
You Benoit
You Benoit
Hôpital Lyon Sud, Pierre-Bénite, France
Fabbro Michel
Fabbro Michel
Icm Montpellier, Montpellier, France

Industries

Voir plus
MSD
10 collaboration(s)
Dernière en 2023
GSK
8 collaboration(s)
Dernière en 2023
Merck-Serono
3 collaboration(s)
Dernière en 2022
AstraZeneca
3 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Nature communications   05 mars 2024
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function: A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies
Essai Clinique (Epizyme, Inc.)   29 février 2024
French national standard for the treatment of squamous cell carcinoma of upper aero-digestive tract - General principles of treatment.
Bulletin du cancer   27 février 2024
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas: A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Essai Clinique (Constellation Pharmaceuticals)   15 février 2024
VICTORIA: A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Essai Clinique (Centre Léon-Bérard)   12 février 2024
TILsOV-1805: Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Advanced High-grade Serous Ovarian Cancer in Blood, Ascites, Peritoneal Biopsy
Essai Clinique (Centre Oscar-Lambret)   08 février 2024
National standard for the treatment of squamous cell carcinoma of upper aerodigestive tract.
Bulletin du cancer   08 février 2024
GYNET: A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.
Essai Clinique (NETRIS Pharma)   24 novembre 2023
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
JAMA network open   01 novembre 2023
752P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023